SearcharxivSearch

arXiv subjects

Stephan Reichl

Publications and source records attributed to Stephan Reichl.

2 recordsLinked to original sources

Smart membrane: high content in situ monitoring barrier on chip with artificial neural network

Conventional transepithelial electrical resistance (TEER) technique provides only a low-content analysis of cell-layer conditions, necessitating repeated microscopic assessments of morphology and cell-cell contacts outside the incubator for barrier-on-chip systems. This work presents a novel high-content TEER device in the form of a novel nanoporous membrane that facilitates continuous electrical measurement of cell-substrate impedance sensing (ECIS). The ultrathin (700 nm) membrane, composed of ultra-low-stress SixNy, is monolithically integrated into wafer-level fabricated chips sealed with glass lids. Coplanar ECIS electrodes were connected to custom electronics to record impedance under sinusoidal excitation. Human umbilical vein endothelial cells (HUVECs) were seeded and continuously recorded impedance spectra were compared with bright-field and fluorescence microscopy, revealing distinct phases of monolayer formation. With one-dimensional convolutional neural network (Conv1d) and Kolmogorov-Arnold Network (KAN) trained with a small amount of Nyquist-diagrams, phases of (I) adherence, (II) outspreading, (III) confluence and (IV) barrier maturity with tight junction formation could be recognized with 95% confidence. As further proof of concept, reversible and irreversible barrier weakening using modulators PN159 and BAC was identified in this way. Our studies have demonstrated that an immediate and automatable non-invasive detection of in-vitro barrier dynamics within barrier-on-chip systems, eliminating the need for microscopy and endpoint staining. We expect this ECIS technique will find broad applications in organ-on-chip systems for in situ monitoring physiological or pathological states of tissue barrier.

eess.SP

What are the limits to biomedical research acceleration through general-purpose AI?

Although general-purpose artificial intelligence (GPAI) is widely expected to accelerate scientific discovery, its practical limits in biomedicine remain unclear. We assess this potential by developing a framework of GPAI capabilities across the biomedical research lifecycle. Our scoping literature review indicates that current GPAI could deliver a speed increase of around 2x, whereas future GPAI could facilitate strong acceleration of up to 25x for physical tasks and 100x for cognitive tasks. However, achieving these gains may be severely limited by factors such as irreducible biological constraints, research infrastructure, data access, and the need for human oversight. Our expert elicitation with eight senior biomedical researchers revealed skepticism regarding the strong acceleration of tasks such as experiment design and execution. In contrast, strong acceleration of manuscript preparation, review and publication processes was deemed plausible. Notably, all experts identified the assimilation of new tools by the scientific community as a critical bottleneck. Realising the potential of GPAI will therefore require more than technological progress; it demands targeted investment in shared automation infrastructure and systemic reforms to research and publication practices.

cs.CY